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Accepted 21 November 2014; Published online 28 November 2014AbstractObjectives: Findings from nonrandomized studies on safety or efficacy of treatment in patient subgroups may trigger postlaunch ran-
domized clinical trials (RCTs). In the analysis of such RCTs, results from nonrandomized studies are typically ignored. This study explores
the trade-off between bias and power of Bayesian RCT analysis incorporating information from nonrandomized studies.
Study Design and Setting: A simulation study was conducted to compare frequentist with Bayesian analyses using noninformative and
informative priors in their ability to detect interaction effects. In simulated subgroups, the effect of a hypothetical treatment differed be-
tween subgroups (odds ratio 1.00 vs. 2.33). Simulations varied in sample size, proportions of the subgroups, and specification of the priors.
Results: As expected, the results for the informative Bayesian analyses were more biased than those from the noninformative Bayesian
analysis or frequentist analysis. However, because of a reduction in posterior variance, informative Bayesian analyses were generally more
powerful to detect an effect. In scenarios where the informative priors were in the opposite direction of the RCT data, type 1 error rates
could be 100% and power 0%.
Conclusion: Bayesian methods incorporating data from nonrandomized studies can meaningfully increase power of interaction tests in
postlaunch RCTs.  2015 Elsevier Inc. All rights reserved.
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Randomized clinical trials (RCTs) are the gold standard to
assess effects of interventions (eg, a drug or surgical proce-
dure). An important reason for this is that random allocation
of treatment prevents confounding. It is well known, howev-
er, that RCTs are usually underpowered to detect adverse
events or treatment effect modification (ie, underpowered
to detect differences in treatment effects between patientThis work has been presented at the 2013 Dutch WEON conference.
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0895-4356/ 2015 Elsevier Inc. All rights reserved.subgroups) [1,2]. It is therefore possible that signals of effect
modification or adverse events are only detected after mar-
keting of the treatment in postlaunch nonrandomized studies
(eg, case-control or cohort studies). Such signals may
then lead to the initiation of new (subgroup-specific) RCTs
in an attempt to provide more evidence on which patient
group(s) benefit (most) from treatment.
An example of treatment effectmodification is the effect of
the oral antidiabetic drug rosiglitazone, a type of thiazolidine-
dione (TZD), on bone fractures: rosiglitazone increases the
risk of bone fractures in women but not in men [3e5].
Customarily, postlaunch RCTs are analyzed without incorpo-
rating information from nonrandomized studies. On the other
hand, including information from nonrandomized studies in
the analysis of RCTs may decrease the required number of
subjects for that trial. This may be particularly important in
nical Epidemiology 68 (2015) 387e396What is new?
Key findings
 Postlaunch randomized clinical trials (RCTs) are usu-
ally initiated to answer questions on intended or unin-
tended effects of therapy in subgroups. Often these
effects are harder to detect than main effects of ther-
apy and therefore require a larger sample of patients.
Depending on the quality of the nonrandomized study
results, incorporating such evidence in the analysis of
postlaunchRCTs can increase power and precision of
results and thus decrease sample size.
What this adds to what was known?
 Nonrandomized studies on therapy effects are
vulnerable to bias. This has led some researchers
to discount results for nonrandomized studies alto-
gether; for example, most systematic reviews focus
exclusively on evidence from RCTs. With the
advent of health care databases, however, data
quality of nonrandomized studies has increased,
potentially decreasing bias. On the other hand,
RCTs have begun using less stringent selection
criteria, resulting in a patient sample better reflect-
ing clinical practice. This article showed that
including results from nonrandomized studies
frequently increases bias. However, this increase
in bias may be outweighed by an increase in power,
precision, and decrease in sample size.
What is the implication and what should change
now?
 Knowledge on intended or unintended subgroup-
specific effects of therapy is important to decide
which patients will benefit from therapy. Because
of sample size constraints, most RCTs are unlikely
to detect these important effects. One possibility to
resolve this is to incorporate results from non-
randomized studies in RCT analysis, using infor-
mative Bayesian priors. Clearly, posterior results
depend heavily on the choice of prior and hence
on the quality of the nonrandomized studies. When
results from RCTs and nonrandomized studies
agree, incorporating results from both study types
results in a meaningful increase in power and preci-
sion. Obviously, when RCTs and nonrandomized
studies disagree, this is not the case. However, in
such scenarios, the benefit of a Bayesian analysis
is that the need for further research, exploring this
contradictory evidence, ismade glaringly apparent.
studies of treatment effect modification or adverse advents
because these typically require considerably more patients
than studies exploring average treatment effects [1,2].
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mation from nonrandomized studies will heavily depend on
the quality (ie, validity) of the latter. Unless the results from
the nonrandomized studies are centered on the RCT
estimate, an increase in bias is likely. However, with the
advent of health care databases [6] developed specifically
for research, such as CPRD (www.cprd.com) or PHARMO
(www.pharmo.nl), the quality of nonrandomized studies
may have increased. For example, these databases may
decrease bias by allowing for better confounder control
through improved data quality, more appropriate selection
of comparators, and a decreased likelihood of loss to
follow-up. Furthermore, if bias is constant across sub-
groups, this will cancel out when assessing the ratio of
treatment effects in two patient subgroups, resulting in a
correct estimate of interaction. For example, assume that
the true risk ratio (RR) in men equals 1.00 and 2.00 in
women; the interaction effect is 1.00/2.00 5 0.50. If both
RRs were biased upward by 40%, for example, due to con-
founding, the interaction effect would still be (1.00  1.40)/
(2.00  1.40) 5 0.50. Unfortunately, the assumption of
equal bias is untestable without knowing the ‘‘true’’ effect.
However, even when this assumption is not exactly met,
estimates of interaction effects will likely be less biased
than main effect estimates. Given that most RCTs lack po-
wer to detect interaction effects and the increased potential
to adjust for confounding in nonrandomized studies, it
might be time to more seriously consider combining results
from both sources.
One way of incorporating information from nonrandom-
ized studies in the analysis of a RCT is by means of
Bayesian statistics [7]. Although not the only way to incor-
porate results from previous studies, Bayesian methods are
intuitively appealing because of their ease of reweighing
prior knowledge, depending on for example its perceived
relevance or validity [8]. Previously, informative Bayesian
methods have been used to include prior knowledge in
phase I and II trials [9,10]. In phase III trials, Bayesian
methods have been used to incorporate prior knowledge
in the analysis of the control group [11]. In this manuscript,
we elaborate on this by exploring the trade-off between bias
and power of a phase IV RCT using prior knowledge from
nonrandomized postmarketing studies. Performance of
such an approach was evaluated using a simulation study,
based on the aforementioned example of effect modifica-
tion by gender of rosiglitazone on the risk of bone fracture.2. Methods
In the following, we first describe the clinical example
of rosiglitazone use and the risk of hip fracture, which
was the starting point for the simulations. Second, we
describe the frequentist and Bayesian analyses that were
performed on the simulated data. Finally, we describe the
different parameters that were varied across simulations.
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RCT data were simulated based on the empirical
example of the effect of rosiglitazone on bone fractures.
Effect estimates were used from a recent meta-analysis
[5] of five RCTs comparing TZDs to placebo or an active
comparator (eg, metformin) on the risk of bone fractures
(Table 1). The odds ratio (OR) of fracture for TZD in
men was 1.00 [95% confidence interval (CI): 0.73, 1.39],
whereas the OR in women was 2.23 (95% CI: 1.65,
3.01), resulting in a treatment by gender interaction effect
of 0.45 (95% CI: 0.29, 0.70). Information from nonrandom-
ized studies was based on a recent individual patient data
meta-analysis (IPDMA) by Bazelier et al. [3] including
data from three nonrandomized studies comparing TZDs
to other oral antidiabetic treatments. This IPDMAwas used
because it presented subgroup-specific effect estimates after
confounding adjustment: OR 1.05 (95% CI: 0.96, 1.14) in
men, OR 1.44 (95% CI: 1.35, 1.53) in women, and an inter-
action OR of 1.05/1.44 5 0.73 (95% CI: 0.66, 0.81;
Table 1).2.2. Statistical analyses
The typical frequentist analysis, a test ignoring prior
knowledge, used by most RCTs was considered as the
reference. We assumed that the gender-specific treatment
effects (the natural logarithm of the OR) were approxi-
mately normally distributed and Wald-based 95% CI were
constructed. Let yi indicates the natural logarithm of the
OR, ln(OR), of rosiglitazone in males (i 5 1) or females
(i 5 2). Interaction effects were calculated by subtracting
y2 from y1, and the variance in the natural logarithm of
the interaction effect was derived by taking the sum of
the variances ½s2i  in gender-specific ln(OR) [12,13].
Bayesian methods were implemented by combining the
previously mentioned gender-specific likelihoods with
conjugate (normally distributed) gender-specific priors:
Nðxi; t2i Þ with the hyperparameter xi representing the
gender-specific mean ln(OR) of treatment and t2i the corre-
sponding variance in xi. Given that the variance ðt2i Þ of an
OR depends on its mean, we assumed this variance to be
known.Table 1. Empirical data on the adverse effect of thiazolidinediones (TZDs) o
effects presented as odds ratio and 95% confidence intervala
Subgroups
RCT data
TZDs effects on bone fractures Interaction effec
Men 1.00 (0.73, 1.39) 0.45 (0.29, 0.7
Women 2.23 (1.65, 3.01) Reference
Abbreviations: TZDs, thiazolidinediones; RCT, randomized clinical trial.
a The empirical RCT data were used to simulate a new RCT and were co
data consisted of 11,401 subjects, of whom 346 experienced a bone fractur
32,244 experienced a bone fracture. Presented RCT effect estimates are
adjusted for potential confounders. Interaction effects are the ratio of the s
is modified by gender.The following four prior distributions were applied.
First, as a reference, a noninformative prior was used, with
hyperparameters xi50 and t
2
i510
6. Second, three informa-
tive prior distributions were used with different precisions
(ie, different variance hyperparameters) denoted skeptical,
equivalent, and optimistic (Fig. 1). For the skeptical prior,
t2i equaled four times the variance in ln(OR) of the simu-
lated RCT: t2i5s
2
i  4. The variance hyperparameter of
the equivalent prior was set equal to the variance in ln(OR)
of the simulated RCT: t2i5s
2
i  1. By setting the variance
hyperparameter proportional to variance in the RCT treat-
ment effect estimates, the skeptical and equivalent priors
prevent the prior information from over influencing the data
[14]. The hyperparameter of the optimistic prior was set to
t2i50:027, which was similar to the precision of the main
effect of original RCT meta-analysis [5].
The hyperparameters of xi were based on the reported
nonrandomized treatment effect estimates presented in
Table 1. To further incorporate the uncertainty around the
true treatment effect, the hyperparameter, xi, was set to
the point estimates [ln(1.05) in men; ln(1.44) in women],
the lower bound of the 95% CI [ln(0.96); ln(1.35)] or the
upper bound [ln(1.14); ln(1.53)] of the gender-specific
treatment effects observed in the empirical IPDMA
(Table 1).
Finally, using the previously defined gender-specific
likelihoods and priors, the posterior mean bui and
variance bd2i were estimated using Equation (1).n bone
ts
0)
mbined
e; the n
unad
ubgroubqi|N
bui5 s2i xi þ t2i yi
s2i þ t2i
; bd2i 5 s2i t2is2i þ t2i

ð1Þ95% credibility intervals (95% CrI) were created using
the posterior mean and the 2.5th and 97.5th percentiles.
Posterior standard deviations for the gender-specific
ln(ORs) of treatment were estimated by taking the square
root of bd2i ; after frequentist practice, these will subse-
quently be referred to as the standard error (SE). The
posterior interaction effect was defined as bu1  bu2, and
the variance in interaction effect was estimated by summing
the variances ðbd2i Þ of the gender-specific treatment effect
estimates (on the natural logarithmic scale) [12,13].fracture incidence within male and female patient subgroups;
Nonrandomized data
TZDs effects on bone fractures Interaction effects
1.05 (0.96, 1.14) 0.73 (0.66, 0.81)
1.44 (1.35, 1.53) Reference
with prior information based on the nonrandomized data. RCT
onrandomized data consisted of 1,637,084 patients, of whom
justed for covariables, whereas nonrandomized estimates are
p-specific effects and measure how much the treatment effect
Fig. 1. Probability density distributions of simulated randomized clinical trial (RCT) data (N 5 5,000) and three informative priors. The mean odds
ratio (OR) of the simulated RCT data was 1.00, 2.23, and 0.45 for the rosiglitazone effect in men, women, and their interaction. For the informative
priors, the mean OR was set to 1.05, 1.44, and 0.73, based on results from nonrandomized studies (see Table 1).
390 A.F. Schmidt et al. / Journal of Clinical Epidemiology 68 (2015) 387e3962.3. Simulations
A basic RCT scenario was created with gender-specific
treatment effects (OR) of 1.00 in men and 2.23 in women re-
sulting in an interaction OR of 0.45. Postlaunch RCTs with
1,000, 5,000, or 10,000 subjects were created. Subjects were
equally divided between exposure groups and between gen-
ders. Dichotomous outcome data (bone fracture yes/no) per
gender-specific subgroup were generated using random
draws from a binomial distribution, with the outcome inci-
dence in the comparator group set to 0.03 in women and
0.02 in men. All simulations were repeated 10,000 times,
using the R statistical package for Windows version 3.0.2,
Vienna, Austria [15].In the basic scenario (I), the type 1 error rate was
explored among males (true OR 5 1.00) and power was
evaluated among females (true OR 5 2.23) and for the
interaction effect (ie, 0.45). To also evaluate type 1 error
rates of the interaction effect, additional scenarios were
created (Table 2). In scenario II, the gender-specific ORs
from the RCT were set to 2.23 in both subgroups, resulting
in an interaction OR of 1.00. In scenario III, the gender-
specific ORs from the RCT were set to 1.00 in both sub-
groups. In scenario IV, we explored the performance of
the Bayesian of interaction tests when the prior information
contradicted the simulated data (OR1 5 1.00 and
OR2 5 2.23), by setting the prior hyperparameter x for
Table 2. Scenarios of a simulation study comparing frequentist to Bayesian analyses of a postlaunch RCTa
Scenario Default (I) II III IV
Sample size 1,000 1,000 1,000 1,000
5,000 5,000 5,000 5,000
10,000 10,000 10,000 10,000
Simulated OR of treatment in men 1.00 2.23 1.00 1.00
Simulated OR of treatment in women 2.23 2.23 1.00 2.23
Prior OR in men 1.05 1.05 1.05 1.44
0.96 0.96 0.96 1.35
1.14 1.14 1.14 1.53
Prior OR of treatment in women 1.44 1.44 1.44 1.05
1.35 1.35 1.35 0.96
1.53 1.53 1.53 1.14
Percentage women includeda 50 50 50 50
Abbreviations: RCT, randomized clinical trial; OR, odds ratio.
a Note all scenarios were repeated using a RCT including 15% women (Appendix). Changes from the default scenario are italicized.
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for women to ln(0.96), ln(1.05), or ln(1.14). Finally, all sce-
narios were repeated with a different gender distribution in
the simulated RCT population: 15% women (results pre-
sented in Appendix Tables 1e4 at www.jclinepi.com).
Performance of the frequentist and Bayesian analyses
was evaluated using mean OR, mean SE, power, type I
error rate, and mean bias. Power was defined as the propor-
tion of times the 95% CrI or 95% CI excluded an OR of 1,
when there was an effect. The type 1 error rate was defined
as the proportion of times the 95% CrI or 95% CI excluded
an OR of 1, when in fact there was no treatment effect.
Mean bias was defined as the mean difference between
the true treatment effect (Table 1, RCT column) and
the estimated treatment effect on the natural logarithmic
scale.3. Results
In the basic scenario (Table 3), subgroup-specific rosigli-
tazone effect estimates in men were around 1.00, indepen-
dent of simulated RCT size and the type of analyses. Type 1
error rates for the frequentist and noninformative priors
were at most 5% and lower for the informative priors (range
0%, 3%). Subgroup-specific treatment effect estimates in
women differed between the analytic methods applied
and depended on the prior. For example, for a sample size
of 1,000, ORs for noninformative, skeptical, equivalent,
and optimistic priors was 2.33, 2.13, 1.83, and 1.51, respec-
tively. Stated otherwise, bias (Table 3) increased by adding
prior knowledge and was largest with the optimistic
Bayesian analysis (bias range 0.04, 0.12). Despite bias
towards a neutral effect of 1, power improved by adding
prior knowledge. For example, in an RCT of 1,000 subjects,
the power to detect a treatment effect in the subgroup of fe-
males was 40% for the frequentist analysis and between
87% and 100% for Bayesian analysis with an optimistic
prior (Table 3). This increase in power was driven by a
decrease in SE that offset the increase in bias. This also
translated in an increased power for the interactiontest: 62% power for the frequentist analysis compared with
83%d93% using an optimistic prior.
To explore the type 1 error rates of the interaction effect, we
simulatedanRCTwhere the trueOR inmenand inwomenwas
2.23 (ie, no interaction). Type 1 error rates of the frequentist,
noninformative prior, and skeptical prior interaction testswere
5% (Table 4). Using an equivalent prior, the type 1 error rate
could be as high as 10% (N5 10,000), but generally, the rate
was below 5% (N5 5,000 or 1,000). Type 1 error rates as high
as 20% were found for Bayesian analyses using optimistic
priors. Finally, in scenarios inwhich themain effectwas absent
(ie, OR in men and women was 1.00, Appendix Table 5 at
www.jclinepi.com), the type 1 error rates of the interaction
testsweregenerally lower,with amaximumof 8%for the opti-
mistic prior.
To assess the impact of incorrectly specifying the prior
mean hyperparameter, analyses were performed in which
the priors contradicted the RCT, for example, a prior inter-
action effect of 1.41 compared with the simulated OR of
0.45 (Table 5). As expected, the frequentist and noninfor-
mative Bayesian analyses showed ORs close to the true
values. Informative Bayesian analyses, using for example,
a sample size of 1,000 subjects, showed ORs in men
ranging from 1.07 (skeptical prior) to 1.49 (optimistic
prior). Similarly, the OR in women ranged from 2.03
(skeptical prior) to 1.05 (optimistic prior). In the same
scenario, interaction effects based on informative priors
ranged from 0.53 (skeptical prior) to 1.26 (optimistic prior).
In these cases, power and type 1 error rates were both
affected, with observed power as low as 0% (ie, interaction
effect and female subgroup) and type 1 error rates as high
as 100% (male subgroup; Table 5).4. Discussion
In this proof of principle study, we showed that, in most
of the explored scenarios, incorporating prior knowledge
using a Bayesian analysis of a postlaunch RCT increases
the power to detect interaction effects at the cost of an in-
crease in bias. For example, in one of our simulations
Table 3. Results of a simulated RCT exploring subgroup-specific and interaction effects using frequentist and Bayesian methodsa
Simulation True OR
N [ 1,000 N [ 5,000 N [ 10,000
OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias
Men 1.00
Frequentist 1.00 (0.71) 2 0.00 1.00 (0.29) 5 0.00 1.00 (0.21) 5 0.00
Noninformative prior 0.99 (0.72) 2 0.01 1.00 (0.29) 4 0.00 1.00 (0.21) 5 0.00
Skeptical prior:
x1 5 ln(1.05) 1.01 (0.64) 1 0.01 1.01 (0.26) 2 0.01 1.01 (0.18) 3 0.01
x1 5 ln(0.96) 0.99 (0.64) 1 0.01 0.99 (0.26) 3 0.01 0.99 (0.18) 3 0.01
x1 5 ln(1.14) 1.02 (0.64) 1 0.02 1.03 (0.26) 3 0.03 1.02 (0.18) 3 0.02
Equivalent prior:
x1 5 ln(1.05) 1.02 (0.51) 0 0.02 1.03 (0.21) 0 0.03 1.02 (0.15) 1 0.02
x1 5 ln(0.96) 0.98 (0.51) 0 0.02 0.98 (0.21) 1 0.02 0.98 (0.15) 1 0.02
x1 5 ln(1.14) 1.06 (0.51) 0 0.06 1.07 (0.21) 1 0.06 1.07 (0.15) 2 0.06
Optimistic prior:
x1 5 ln(1.05) 1.05 (0.16) 0 0.05 1.04 (0.14) 0 0.04 1.03 (0.13) 0 0.03
x1 5 ln(0.96) 0.96 (0.16) 0 0.04 0.97 (0.14) 0 0.03 0.98 (0.13) 0 0.03
x1 5 ln(1.14) 1.13 (0.16) 0 0.12 1.11 (0.14) 0 0.10 1.08 (0.13) 2 0.08
Women 2.23
Frequentist 2.32 (0.48) 40 0.04 2.25 (0.21) 98 0.01 2.24 (0.15) 100 0.00
Noninformative prior 2.33 (0.48) 41 0.05 2.26 (0.21) 98 0.01 2.23 (0.15) 100 0.00
Skeptical prior:
x2 5 ln(1.44) 2.13 (0.43) 40 0.04 2.06 (0.18) 99 0.08 2.05 (0.13) 100 0.08
x2 5 ln(1.35) 2.10 (0.43) 38 0.06 2.03 (0.18) 99 0.09 2.03 (0.13) 100 0.10
x2 5 ln(1.53) 2.14 (0.43) 40 0.04 2.08 (0.18) 99 0.07 2.07 (0.13) 100 0.07
Equivalent prior:
x2 5 ln(1.44) 1.83 (0.34) 38 0.20 1.80 (0.15) 100 0.21 1.80 (0.10) 100 0.22
x2 5 ln(1.35) 1.77 (0.34) 33 0.23 1.74 (0.15) 100 0.25 1.74 (0.10) 100 0.25
x2 5 ln(1.53) 1.89 (0.34) 45 0.17 1.86 (0.15) 100 0.18 1.85 (0.10) 100 0.18
Optimistic prior:
x2 5 ln(1.44) 1.51 (0.16) 99 0.39 1.71 (0.13) 100 0.27 1.84 (0.11) 100 0.19
x2 5 ln(1.35) 1.42 (0.16) 87 0.45 1.64 (0.13) 100 0.31 1.79 (0.11) 100 0.22
x2 5 ln(1.53) 1.59 (0.16) 100 0.34 1.77 (0.13) 100 0.23 1.89 (0.11) 100 0.16
Interaction 0.45
Frequentist 0.43 (0.87) 16 0.04 0.44 (0.36) 62 0.01 0.45 (0.25) 89 0.01
Noninformative prior 0.42 (0.87) 16 0.06 0.44 (0.36) 63 0.01 0.45 (0.25) 90 0.00
Skeptical prior:
x1
x2
5 ln(0.73) 0.48 (0.78) 12 0.06 0.49 (0.32) 61 0.09 0.49 (0.23) 91 0.09
x1
x2
5 ln(0.71) 0.47 (0.78) 12 0.05 0.49 (0.32) 62 0.08 0.49 (0.23) 91 0.09
x1
x2
5 ln(0.75) 0.48 (0.78) 12 0.07 0.49 (0.32) 62 0.09 0.49 (0.23) 90 0.10
Equivalent prior:
x1
x2
5 ln(0.73) 0.56 (0.62) 6 0.22 0.57 (0.25) 65 0.24 0.57 (0.18) 95 0.24
x1
x2
5 ln(0.71) 0.55 (0.62) 6 0.21 0.56 (0.25) 67 0.23 0.56 (0.18) 96 0.23
x1
x2
5 ln(0.75) 0.56 (0.62) 6 0.22 0.57 (0.25) 63 0.25 0.57 (0.18) 95 0.25
Optimistic prior:
x1
x2
5 ln(0.73) 0.70 (0.22) 8 0.44 0.61 (0.19) 88 0.31 0.56 (0.17) 99 0.22
x1
x2
5 ln(0.71) 0.68 (0.22) 19 0.41 0.59 (0.19) 93 0.28 0.54 (0.17) 99 0.19
x1
x2
5 ln(0.75) 0.71 (0.22) 3 0.46 0.62 (0.19) 83 0.33 0.57 (0.17) 98 0.24
Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error.
a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis
ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator
reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard
errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or cred-
ibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is
based on a normal distribution with a mean hyperparameter of 0 and variance of 106; the equivalent prior is based on a normal distribution with the
reported ln OR xi and variance hyperparameter t
2
i equal to the simulated data; the skeptical prior uses the same mean and variance hyperpara-
meters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses
a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions.
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62% using a frequentist approach compared with a power
of 83% (93% using a Bayesian approach). Bias increased
from 0.01 for the frequentist estimate to at most 0.33
for the Bayesian estimate. Alternatively phrased, to gain asimilar power (62%) as the frequentist analysis, the
Bayesian method required 22%d48% fewer patients (ie,
3,914; 2,586 subjects instead of 5,000 subjects). This in-
crease in power (or decrease in sample size) is clearly rele-
vant for the detection of treatment effect modification
Table 4. Results of a simulated RCT exploring subgroup-specific and interaction effects using frequentist and Bayesian methods in the presence of
an interaction effect of 1.00a
Simulation True OR
N [ 1,000 N [ 5,000 N [ 10,000
OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias
Men 2.23
Frequentist 2.36 (0.60) 28 0.06 2.25 (0.25) 91 0.01 2.24 (0.18) 100 0.00
Noninformative prior 2.34 (0.60) 27 0.05 2.26 (0.25) 92 0.01 2.24 (0.18) 100 0.01
Skeptical prior:
x1 5 ln(1.05) 2.01 (0.54) 17 0.10 1.95 (0.22) 89 0.14 1.93 (0.16) 99 0.15
x1 5 ln(0.96) 1.98 (0.54) 17 0.12 1.90 (0.22) 87 0.16 1.89 (0.16) 100 0.17
x1 5 ln(1.14) 2.04 (0.53) 19 0.09 1.96 (0.22) 90 0.13 1.96 (0.16) 100 0.13
Equivalent prior:
x1 5 ln(1.05) 1.57 (0.42) 3 0.35 1.54 (0.18) 78 0.37 1.54 (0.12) 99 0.37
x1 5 ln(0.96) 1.51 (0.42) 2 0.39 1.47 (0.18) 63 0.42 1.47 (0.12) 96 0.42
x1 5 ln(1.14) 1.63 (0.42) 5 0.31 1.60 (0.18) 86 0.33 1.60 (0.12) 100 0.33
Optimistic prior:
x1 5 ln(1.05) 1.11 (0.16) 0 0.70 1.32 (0.14) 57 0.53 1.49 (0.12) 99 0.40
x1 5 ln(0.96) 1.02 (0.16) 0 0.78 1.24 (0.14) 18 0.59 1.42 (0.12) 95 0.45
x1 5 ln(1.14) 1.19 (0.16) 0 0.62 1.39 (0.14) 84 0.47 1.56 (0.12) 100 0.36
Women 2.23
Frequentist 2.32 (0.48) 40 0.04 2.25 (0.21) 98 0.01 2.24 (0.15) 100 0.01
Noninformative prior 2.32 (0.48) 41 0.04 2.25 (0.21) 98 0.01 2.24 (0.15) 100 0.00
Skeptical prior:
x2 5 ln(1.44) 2.12 (0.43) 39 0.05 2.05 (0.18) 99 0.08 2.05 (0.13) 100 0.08
x2 5 ln(1.35) 2.07 (0.43) 37 0.07 2.03 (0.18) 99 0.09 2.02 (0.13) 100 0.10
x2 5 ln(1.53) 2.13 (0.43) 40 0.04 2.08 (0.18) 99 0.07 2.08 (0.13) 100 0.07
Equivalent prior:
x2 5 ln(1.44) 1.83 (0.34) 39 0.20 1.80 (0.15) 100 0.21 1.80 (0.10) 100 0.22
x2 5 ln(1.35) 1.77 (0.34) 32 0.23 1.74 (0.15) 100 0.25 1.74 (0.10) 100 0.25
x2 5 ln(1.53) 1.88 (0.34) 44 0.17 1.85 (0.15) 100 0.19 1.85 (0.10) 100 0.19
Optimistic prior:
x2 5 ln(1.44) 1.51 (0.16) 98 0.39 1.71 (0.13) 100 0.27 1.84 (0.11) 100 0.19
x2 5 ln(1.35) 1.42 (0.16) 86 0.45 1.64 (0.13) 100 0.31 1.79 (0.11) 100 0.22
x2 5 ln(1.53) 1.59 (0.16) 100 0.34 1.77 (0.13) 100 0.23 1.89 (0.11) 100 0.16
Interaction 1.00
Frequentist 1.02 (0.77) 4 0.01 1.00 (0.33) 5 0.00 1.00 (0.23) 5 0.00
Noninformative prior 1.01 (0.77) 4 0.01 1.01 (0.33) 5 0.01 1.00 (0.23) 5 0.00
Skeptical prior:
x1
x2
5 ln(0.73) 0.95 (0.69) 2 0.07 0.95 (0.29) 3 0.05 0.94 (0.20) 4 0.06
x1
x2
5 ln(0.71) 0.95 (0.69) 2 0.06 0.94 (0.29) 4 0.06 0.93 (0.20) 4 0.07
x1
x2
5 ln(0.75) 0.96 (0.69) 2 0.07 0.94 (0.29) 4 0.06 0.94 (0.20) 4 0.06
Equivalent prior:
x1
x2
5 ln(0.73) 0.86 (0.55) 1 0.15 0.86 (0.23) 4 0.15 0.86 (0.16) 9 0.16
x1
x2
5 ln(0.71) 0.85 (0.55) 1 0.17 0.84 (0.23) 4 0.17 0.84 (0.16) 10 0.17
x1
x2
5 ln(0.75) 0.87 (0.55) 1 0.15 0.87 (0.23) 3 0.14 0.86 (0.16) 7 0.15
Optimistic prior:
x1
x2
5 ln(0.73) 0.74 (0.22) 1 0.30 0.77 (0.19) 13 0.26 0.81 (0.16) 15 0.21
x1
x2
5 ln(0.71) 0.72 (0.22) 3 0.32 0.76 (0.19) 17 0.28 0.79 (0.16) 20 0.23
x1
x2
5 ln(0.75) 0.75 (0.22) 0 0.28 0.79 (0.19) 9 0.24 0.82 (0.16) 12 0.19
Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error.
a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis
ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator
reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard
errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or cred-
ibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is
based on a normal distribution with a mean hyperparameter of 0 and variance of 106; the equivalent prior is based on a normal distribution with the
reported ln OR xi and variance hyperparameter t
2
i equal to the simulated data; the skeptical prior uses the same mean and variance hyperpara-
meters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses
a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions.
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underpowered.
Previous research on Bayesian RCT analyses [7,16,17],
somealso focusingon effectmodification [18e20], shows thatnoninformative priors could be used to guard against multi-
plicity. Use of informative priors has also been considered.
Most focus on using expert opinion to elicitate prior distribu-
tions [21e24]. These studies show that, if done carefully,
Table 5. Results of a simulated RCT exploring subgroup-specific and interaction effects using frequentist and Bayesian methods showing the impact
of misspecified priorsa
Simulation True OR
N [ 1,000 N [ 5,000 N [ 10,000
OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias OR (SE) Reject (%) Bias
Men 1.00
Frequentist 0.99 (0.72) 2 0.01 1.00 (0.29) 5 0.01 1.00 (0.21) 5 0.00
Noninformative prior 1.00 (0.72) 2 0.00 1.00 (0.29) 5 0.00 1.00 (0.21) 4 0.00
Skeptical prior:
x2 5 ln(1.44) 1.08 (0.64) 1 0.07 1.08 (0.26) 4 0.07 1.07 (0.18) 4 0.07
x2 5 ln(1.35) 1.07 (0.64) 1 0.07 1.06 (0.26) 3 0.07 1.06 (0.18) 4 0.06
x2 5 ln(1.53) 1.08 (0.64) 1 0.08 1.09 (0.26) 3 0.08 1.09 (0.18) 5 0.08
Equivalent prior:
x2 5 ln(1.44) 1.19 (0.51) 0 0.18 1.20 (0.21) 6 0.18 1.20 (0.15) 16 0.18
x2 5 ln(1.35) 1.16 (0.51) 0 0.15 1.16 (0.21) 4 0.15 1.16 (0.15) 9 0.15
x2 5 ln(1.53) 1.24 (0.51) 0 0.22 1.23 (0.21) 9 0.22 1.24 (0.15) 24 0.21
Optimistic prior:
x2 5 ln(1.44) 1.41 (0.16) 82 0.34 1.32 (0.14) 47 0.34 1.25 (0.13) 36 0.22
x2 5 ln(1.35) 1.33 (0.16) 21 0.28 1.26 (0.14) 22 0.28 1.20 (0.13) 20 0.18
x2 5 ln(1.53) 1.49 (0.16) 100 0.40 1.38 (0.14) 73 0.40 1.30 (0.13) 54 0.26
Women 2.23
Frequentist 2.34 (0.49) 41 0.05 2.25 (0.21) 98 0.01 2.24 (0.15) 100 0.00
Noninformative prior 2.30 (0.48) 40 0.03 2.25 (0.21) 98 0.01 2.24 (0.15) 100 0.00
Skeptical prior:
x1 5 ln(1.05) 1.98 (0.43) 31 0.12 1.93 (0.18) 97 0.14 1.92 (0.13) 100 0.15
x1 5 ln(0.96) 1.96 (0.43) 30 0.13 1.89 (0.18) 96 0.16 1.89 (0.13) 100 0.17
x1 5 ln(1.14) 2.03 (0.43) 34 0.09 1.97 (0.18) 98 0.13 1.96 (0.13) 100 0.13
Equivalent prior:
x1 5 ln(1.05) 1.57 (0.34) 13 0.35 1.54 (0.15) 93 0.37 1.53 (0.10) 100 0.37
x1 5 ln(0.96) 1.50 (0.34) 8 0.40 1.47 (0.15) 86 0.42 1.47 (0.10) 100 0.42
x1 5 ln(1.14) 1.63 (0.34) 18 0.31 1.60 (0.15) 98 0.33 1.60 (0.10) 100 0.33
Optimistic prior:
x1 5 ln(1.05) 1.14 (0.16) 0 0.67 1.41 (0.13) 91 0.46 1.60 (0.11) 100 0.33
x1 5 ln(0.96) 1.05 (0.16) 0 0.75 1.33 (0.13) 72 0.51 1.54 (0.11) 100 0.37
x1 5 ln(1.14) 1.22 (0.16) 0 0.60 1.48 (0.13) 97 0.41 1.66 (0.11) 100 0.29
Interaction 0.45
Frequentist 0.42 (0.87) 16 0.06 0.44 (0.36) 62 0.01 0.45 (0.25) 89 0.00
Noninformative prior 0.43 (0.87) 15 0.03 0.45 (0.36) 62 0.01 0.45 (0.25) 89 0.00
Skeptical prior:
x1
x2
5 ln(1.37) 0.55 (0.78) 8 0.20 0.56 (0.32) 44 0.22 0.56 (0.23) 76 0.22
x1
x2
5 ln(1.41) 0.55 (0.78) 8 0.20 0.56 (0.32) 43 0.22 0.56 (0.23) 75 0.22
x1
x2
5 ln(1.34) 0.53 (0.78) 8 0.17 0.55 (0.32) 45 0.21 0.56 (0.23) 77 0.22
Equivalent prior:
x1
x2
5 ln(1.37) 0.76 (0.62) 1 0.53 0.78 (0.25) 8 0.56 0.78 (0.18) 21 0.56
x1
x2
5 ln(1.41) 0.78 (0.62) 0 0.55 0.79 (0.25) 7 0.57 0.79 (0.18) 17 0.57
x1
x2
5 ln(1.34) 0.76 (0.61) 1 0.53 0.77 (0.25) 9 0.54 0.78 (0.18) 22 0.55
Optimistic prior:
x1
x2
5 ln(1.37) 1.24 (0.22) 0 1.02 0.94 (0.19) 0 0.74 0.78 (0.17) 23 0.55
x1
x2
5 ln(1.41) 1.26 (0.22) 0 1.04 0.94 (0.19) 0 0.74 0.78 (0.17) 22 0.55
x1
x2
5 ln(1.34) 1.22 (0.22) 0 1.00 0.93 (0.19) 0 0.73 0.78 (0.17) 23 0.55
Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error.
a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis
ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator
reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard
errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or cred-
ibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is
based on a normal distribution with a mean hyperparameter of 0 and variance of 106; the equivalent prior is based on a normal distribution with the
reported ln OR xi and variance hyperparameter t
2
i equal to the simulated data; the skeptical prior uses the same mean and variance hyperpara-
meters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses
a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions.
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based prior distributions. Our manuscript contributes to these
articles by focusing on prior distributions based on non-
randomized study results. To some researchers, usinginformative priors based on nonrandomized studies may seem
more objective than using expert opinion. However, there is
still subjectivity about which nonrandomized studies to
include and which variance hyperparameter to choose.
395A.F. Schmidt et al. / Journal of Clinical Epidemiology 68 (2015) 387e396We feel that the following points deserve discussion.
First, the Bayesian analyses of RCTs were evaluated based
on power and type 1 error. These metrics are usually exclu-
sive to frequentist analyses after the NeymanePearson
perspective. However, given that, at completion of a post-
launch RCT, decisions may have to be made on continued
market access, for example, by drug regulatory agencies
such as EMA or FDA, we feel that these metrics are rele-
vant [25,26]. Second, it might seem inappropriate to
combine information from nonrandomized studies with
RCT data because the results of RCTs are typically of high-
er quality. However, it seems equally inappropriate to
exclude information simply because treatment was not
randomly allocated, especially in studies of adverse events
[27e29]. We feel that it is time for a more inclusive view
on interventional research formally incorporating informa-
tion from multiple sources.
To reach such an inclusive view, we wish to note the
following. We showed that Bayesian RCT analyses, using
informative priors, can increase power at the potential
cost of an increase in bias. This trade-off between power
and bias might be acceptable for interaction effects
because the power of interaction tests is notoriously
limited [1,13,30]. Also note that including prior knowl-
edge in an RCT analysis does not necessarily always in-
crease bias. For example, because the prior for the male
subgroup-specific effect was very compatible with the
RCT estimate (eg, Table 3), the posterior effect estimate
was practically unbiased. Because of the inclusion of
prior information, however, the posterior estimate was
more precise than the frequentist or noninformative esti-
mates. When designing an RCT, we suggest that if one
is confident about the direction of an effect, an informa-
tive prior based on nonrandomized studies might be used.
This will result in a decrease in the number of patients
who need to be randomized to a potentially inferior treat-
ment, a reduction in costs, and in posterior effect esti-
mates reflecting all available (nonconflicting) evidence.
In designing such a Bayesian postlaunch RCT, similar
to the more familiar sample size calculation, we suggest
researchers to use simulations to gain insight in how the
prior knowledge may influence the posterior distribution.
If, after data collection, the RCT data unexpectedly
contradict the prior distribution, the use of informative
priors might seem inappropriate. Indeed, our simulations
showed a large increase in type 1 error rate and almost
meaningless power. However, instead of simply ignoring
the nonrandomized study results, as is current practice,
we feel that in such settings, it is essential to discuss
and explore why RCTs and prior information differed.
To be meaningful, this discussion should go beyond a
statement on the hierarchy of study design and the known
shortcomings of nonrandomized studies (most notably the
potential for confounding). Furthermore, the possibility
that the data and the prior information disagree might
seem a shortcoming of Bayesian RCT analyses. We feel,however, that when the data contradict the prior informa-
tion, further research is needed. Because Bayesian
methods will emphasize such contradictory findings and
fuel the need for additional research, we see this as a vir-
tue rather than a shortcoming.
Specifically, for the analysis of adverse events, it is
important to take into account the type of adverse event
(A or B) [31,32]. Type A adverse events result from the
primary mechanism of action of the intervention. There-
fore, confounding by indication seems more likely, and
this should be reflected in the prior distribution. However,
for type B adverse events, the underlying mechanism is
often unknown, thus decreasing the potential for con-
founding that should also be reflected in the prior belief.
Initiating an RCT to study adverse events (notably type
B) seems unlikely (due to the huge sample size typically
required). However, pooling results from RCTs (initiated
to study an intended effect) and nonrandomized studies
on adverse event (using Bayesian methods) appears a
viable and highly advisable alternative.
In conclusion, Bayesian analysis of postlaunch RCTs
using informative priors will likely bias estimates of treat-
ment effects. However, when the prior information and
the expected RCT results are in the same direction, the
decrease in variance can lead to relatively higher power
of the Bayesian analysis with an acceptable degree of
bias. This trade-off between power and bias might be
acceptable for interaction effects because most RCTs only
have limited power to detect these effects.Acknowledgments
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